BIG PHARMA SPLIT CL.A
Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc. It invests in the public equity markets across United States. The fund primarily invests in the Pharmaceutical sector. Big Pharma Split Corp was formed on September 15, 2017 and is domiciled in Canada.
Market Cap & Net Worth: BIG PHARMA SPLIT CL.A (XN4)
BIG PHARMA SPLIT CL.A (F:XN4) has a market capitalization of $11.23 Million (€10.94 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #41358 globally and #6239 in its home market, demonstrating a 3.45% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BIG PHARMA SPLIT CL.A's stock price €9.00 by its total outstanding shares 1216038 (1.22 Million).
BIG PHARMA SPLIT CL.A Market Cap History: 2022 to 2026
BIG PHARMA SPLIT CL.A's market capitalization history from 2022 to 2026. Data shows growth from $9.73 Million to $11.23 Million (4.63% CAGR).
BIG PHARMA SPLIT CL.A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BIG PHARMA SPLIT CL.A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of XN4 by Market Capitalization
Companies near BIG PHARMA SPLIT CL.A in the global market cap rankings as of March 19, 2026.
Key companies related to BIG PHARMA SPLIT CL.A by market ranking:
- Four Arrows Capital Corp (V:AROW-P): Ranked #41349 globally with a market cap of $87.02K USD ( CA$124.98K CAD).
- Iljin Diamond Co. Ltd. (KQ:081000): Ranked #41350 globally with a market cap of $86.93K USD ( ₩127.29 Million KRW).
- BROOKDALE SR LIVING (BE:B7S): Ranked #41359 globally with a market cap of $86.38K USD ( €84.16K EUR).
- Samurai Capital Corp (V:SSS-P): Ranked #41360 globally with a market cap of $86.34K USD ( CA$124.00K CAD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #41349 | Four Arrows Capital Corp | V:AROW-P | $87.02K | CA$0.05 |
| #41350 | Iljin Diamond Co. Ltd. | KQ:081000 | $86.93K | ₩13540.00 |
| #41359 | BROOKDALE SR LIVING | BE:B7S | $86.38K | €9.10 |
| #41360 | Samurai Capital Corp | V:SSS-P | $86.34K | CA$0.04 |
BIG PHARMA SPLIT CL.A Historical Marketcap From 2022 to 2026
Between 2022 and today, BIG PHARMA SPLIT CL.A's market cap moved from $9.73 Million to $ 11.23 Million, with a yearly change of 4.63%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €11.23 Million | +5.88% |
| 2025 | €10.61 Million | -2.86% |
| 2024 | €10.92 Million | +8.28% |
| 2023 | €10.09 Million | +3.63% |
| 2022 | €9.73 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of BIG PHARMA SPLIT CL.A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.23 Million USD |
| MoneyControl | $11.23 Million USD |
| MarketWatch | $11.23 Million USD |
| marketcap.company | $11.23 Million USD |
| Reuters | $11.23 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.